To include your compound in the COVID-19 Resource Center, submit it here.

April 1 Quick Takes: Gedeon gets Europe rights to Myovant’s uterine fibroid therapy following MAA submission; plus Orion-Bayer, BMS-bluebird, Mesoblast and more

Myovant licenses relugolix rights to Gideon for $40M
Myovant Sciences GmbH (NYSE:MYOV) licensed rights of relugolix combination tablets to Gedeon Richter plc (Budapest:RICHTER) in Europe, Russia, Latin America, Australia and New Zealand. Myovant, which retains U.S. rights, will receive $40 million up front

Read the full 425 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers